Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tumor marker may guide chemo choice for rare cancers

NCT ID NCT03217097

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 116 people with advanced neuroendocrine tumors to see if a marker called MGMT can predict which chemotherapy works best. Researchers compared two chemo types—alkylating agents and oxaliplatin—based on MGMT status. The goal is to personalize treatment and improve response rates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

116 people

The number who actually took part.

Started

Oct 2018

Finished

Apr 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age greater than or equal to 18 years; * Patient presenting well-differentiated advanced grade 1-3 (locally/metastatic) duodeno-pancreatic or thoracic (lung or thymus) or unknown primitive NETs, not curable with surgery. * Patients must have measurable disease using the RECIST v1.1 criteria; * Indication for cytotoxic systemic chemotherapy validated by the dedicated Multidisciplinary Tumor Board; * MRI or TAP CT scan with contrast agents within 4 weeks +/- 1 week before beginning of treatment; * Tumor tissue available (fresh frozen or paraffin-embedded) in order to search for the methyl guanine methyltransferase (MGMT) status; * Patients with childbearing potential should use effective contraception during the study and the following 6 months; * Covered by a Healthcare System where applicable, and/or in compliance with the recommendations of the national laws in force relating to biomedical research; * Subject able to understand and willing to sign a written informed consent document; * Signed written informed consent obtained prior to any study-specific screening procedures. Previous treatments such as surgery, radiofrequency ablation, transarterial liver embolization, somatostatin analogs, interferon, everolimus or other targeted therapy, peptide receptor radionuclide treatment (PRRT) and chemotherapy (platin-etoposide, folfiri, paclitaxel or docetaxel) are allowed. Exclusion Criteria: * Previous chemotherapy using Oxaliplatin or ALKY (streptozotocin, dacarbazin or temozolomide). Other chemotherapy (platin-etoposide, folfiri, paclitaxel or docetaxel) are allowed; * Pregnant or breastfeeding; * Men and women of childbearing age potential not using medically accepted contraceptive measures, as judged by the investigator; * Contraindication to any drug contained in the chemotherapy regimen; * Any significant disease which, in the investigator's opinion, excludes the patient from the study; * Under any administrative or legal supervision.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neuroendocrine tumors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neuroendocrine tumors

Contacts and locations

Locations

  • CH Annecy Genevois

    Pringy, 74374, France

  • CHU d'Angers

    Angers, 49933, France

  • Centre Oscar Lambret

    Lille, 59020, France

  • Hôpital Beaujon - APHP

    Clichy, 92118, France

  • Hôpital Claude Hurriet - CHRU Lille

    Lille, 59037, France

  • Hôpital Cochin - APHP

    Paris, 75014, France

  • Hôpital Edouard Herriot - Hospices Civils de Lyon

    Lyon, 69003, France

  • Hôpital Estaing, CHU de Clermont-Ferrand

    Clermont-Ferrand, 63003, France

  • Hôpital François Mitterrand - CHU Dijon Bourgogne

    Dijon, 21000, France

  • Hôpital Nord - CHU Saint Etienne

    Saint-Priest-en-Jarez, 42270, France

  • Hôpital Privé Jean Mermoz

    Lyon, 69008, France

  • Hôpital Rangueil - CHU Toulouse

    Toulouse, 31059, France

  • Hôpital Robert Debré - CHU Reims

    Reims, 51092, France

  • Hôpital Saint Louis - APHP

    Paris, 75010, France

  • Hôpital Sud - CHU Amiens

    Amiens, 80054, France

  • Hôpital Trousseau - CHU Tours

    Tours, 37044, France

  • Institut Gustave Roussy

    Villejuif, 94805, France

  • Institut Paoli Calmettes

    Marseille, 13009, France

  • Institut de Cancérologie de la Loire

    Saint-Priest-en-Jarez, 42270, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.